4Sc

4Sc Equity

Delisted

The The Equity of 4Sc (VSC.DE) as of Nov 3, 2026 is 13.29 M EUR. In the previous year, The Equity was 27.67 M EUR — a change of -51.97% (lower).

Equity

13.29 MEUR

YoY

-51.97%

Last updated:

In 2022, 4Sc's equity was 13.29 M EUR, a -51.97% increase from the 27.67 M EUR equity in the previous year.

The 4Sc Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
26.43 M EUR
Jan 1, 2016
15.27 M EUR
Jan 1, 2017
44.69 M EUR
Jan 1, 2018
28.45 M EUR
Jan 1, 2019
48.19 M EUR
Jan 1, 2020
37.45 M EUR
Jan 1, 2021
27.67 M EUR
Jan 1, 2022
13.29 M EUR
The 4Sc Equity history
YEAREquityYoY
13.29 MEUR-51.97%
27.67 MEUR-26.11%
37.45 MEUR-22.30%
48.19 MEUR+69.37%
28.45 MEUR-36.34%
44.69 MEUR+192.63%
15.27 MEUR-42.21%
26.43 MEUR+1,189.17%
2.05 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

4Sc Stock analysis

What does 4Sc do? The 4Sc AG is a German biotechnology company specializing in the discovery and development of drugs for numerous indications. It was founded in 2007 and focuses on innovative immunotherapies against cancer, autoimmune diseases, and inflammation. The company's goal is to bring promising drug candidates to Phase IIb clinical trials and then license them to partner companies. Its business model involves working with academic and clinical institutions to research and expand its pipeline. The company's portfolio is divided into three main areas: oncology, autoimmune diseases, and inflammation. It develops drugs that utilize the body's immune system to target cancer cells, inhibit inflammation for autoimmune diseases, and specifically target inflammation for other conditions. Overall, 4Sc AG aims to discover and develop novel drugs that can help patients with severe medical conditions. 4Sc is one of the most popular companies on Eulerpool.

Equity Details

Analyzing 4Sc's Equity

4Sc's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding 4Sc's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating 4Sc's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

4Sc's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in 4Sc’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about 4Sc stock

The Equity of 4Sc is 13.29 M EUR in 2022.

The Equity of 4Sc changed from 27.67 M EUR to 13.29 M EUR, representing a -51.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity 4Sc since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's 4Sc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — 4Sc

All Key Metrics — 4Sc